Q-omics provides the consensus-scored CBX5 profile across patient tissues and cancer cell-line models. CBX5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CBX5 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, CBX5 protein abundance shows 24,756 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCS, KIRP, and GBM as cancer lineages where CBX5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CBX5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CBX5 survival associations across molecular data types. CBX5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CBX5 RNA expression–survival associations across cancer types. High CBX5 expression shows unfavorable associations in LUAD, UVM and KICH, but favorable associations in UCS, HNSC and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for CBX5 RNA expression.
This table summarizes CBX5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CBX5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CBX5 shows lower tumor expression in THCA and higher tumor expression in KIRP, LIHC, HNSC, LUSC and LUAD. The KIRP box plot shows higher CBX5 RNA expression in tumor versus normal tissue (log2 FC = +0.968, t-test p < 0.001).
This table shows molecular features associated with CBX5 in patient tissues and cancer cell lines. In patient samples, CBX5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CBX5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
